Invasive NSTEMI Strategy Shows No Benefit in Frail Patients
Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.
By
Kathryn Wighton
May 6, 2026
Clinical Scorecard: Invasive NSTEMI Strategy Shows No Benefit in Frail Patients
At a Glance
Category Detail
Condition Non-ST-Elevation Myocardial Infarction (NSTEMI) in Frail Patients Key Mechanisms Comparison of invasive strategy versus conservative management in frail patients aged 75 and older. Target Population Patients aged 75 years or older with frailty and NSTEMI. Care Setting Cardiology, specifically in the context of acute coronary syndrome management.
Key Highlights
Invasive strategy did not reduce cardiovascular death or nonfatal myocardial infarction compared to conservative management. Higher frailty levels were associated with worse outcomes in invasive management. 38% of invasive care patients experienced primary outcome versus 29% in conservative care. Procedural complications were numerically more common in frail patients undergoing invasive treatment. Findings suggest frailty modifies the balance of benefit and risk with invasive strategies. Guideline-Based Recommendations
Diagnosis
Assess frailty using Fried frailty criteria in patients with NSTEMI. Management
Consider conservative management for frail patients with NSTEMI. Monitoring & Follow-up
Monitor for procedural complications in frail patients undergoing invasive procedures. Risks
Be aware of potential harm associated with invasive strategies in patients with higher frailty. Patient & Prescribing Data
Frail patients aged 75 years or older with NSTEMI.
Invasive management may not provide expected benefits and could increase risks in frail patients.
Clinical Best Practices
Evaluate frailty severity when making treatment decisions for older patients. Utilize conservative management strategies in frail patients with NSTEMI. References
